September 18th, 2007
Rehovot, Israel – September 18th, 2007 – Evogene Ltd. (TASE: EVGN) announces that yesterday, at its Annual Meeting of Shareholders, Dr. Michael Anghel and Dr. Rafi Hofstein were elected to serve as external directors of the Company.
Dr. Michael Anghel serves as a member of various boards of major Israeli corporations, including Partner Ltd., Syneron Medical Ltd., ECI Telecom Ltd., and Scopus Ltd. Previously, Dr. Anghel served on the management of the Discount Investment Corporation and as CEO of Discount Capital Markets, the investment banking arm of the Israel Discount Bank. He was actively involved in the founding and management of various technology and communications enterprises, including Cellcom and Tevel. Dr. Anghel holds a B.A. (Economics) from the Hebrew University in Jerusalem and an M.B.A. and Ph.D. from Columbia University in New York.
Dr. Rafi Hofstein is President and CEO of Hadasit Ltd., the Technology Holdings Company of Hadassah Medical Organization. Previously, he served as the President of Mindsense Biosystems Ltd. and as Business Unit Director of Ecogen Inc. in Langhorne PA, after serving as the Scientific Director of its Israel office. Dr. Hofstein received his PhD and Master of Science in life-sciences and chemistry from the Weizmann Institute of Science, and completed postdoctoral training at the Harvard Medical School in Boston, MA, in the departments of biological chemistry and neurobiology.
Following yesterday’s election by the shareholders, Evogene’s board of directors consists of seven members: Dr. Angel, Martin Gerstel, Dr. Hofstein, Dr. Adina Makover, Leon Recanati, Dr. Simcha Sadan and Dr. Eli Zangvil.
About Evogene
Evogene’s mission is to be a world leader in delivering improved plant traits to the agro-biotechnology and biofuel industries through the use of a continuously improving proprietary platform that combines state-of-the-art computational genomics, molecular biology and advanced breeding methods. Evogene’s current product development portfolio includes such traits as: improved abiotic stress tolerance and yield, enhanced cotton fiber quality, improved nitrogen use efficiency, increased oil yield for biodiesel use and plant manufacturing of therapeutic proteins. Evogene was founded in 2002 as a spin-off of the agro-biotechnology division of Compugen Ltd. (Nasdaq: CGEN) and its core in-silico technology, the ATHLETE, is based on Compugen’s proprietary LEADS computational platform. Evogene completed an IPO on the Tel Aviv Stock Exchange in June 2007 (TASE: EVGN).
For additional information, please visit Evogene’s website at www.evogene.com
This press release contains "forward-looking statements." These statements include words like "may," "expects," "believes," “scheduled” and "intends," and describe opinions about future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of Evogene Ltd. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.
Contact Information
Evogene:
Liat Cinamon
PR & IR Executive
Tel: +972-8-931-1933
E-mail: cinamonl@evogene.com
print page |
